The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses Phase III trials investigating the combination of the JAK inhibitor ruxolitinib with pelabresib (MANIFEST-2; NCT02158858) or navitoclax (TRANSFORM-1; NCT04472598) for patients with myelofibrosis (MF). The results from these trials demonstrate the superiority of this combination in reducing splenomegaly compared to ruxolitinib alone, signaling a shift from JAK inhibitor monotherapy towards combination therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma., a Sobi Company, Mays Cancer Center, NCI; Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
